Which angiosarcoma subtypes may benefit from immunotherapy?
Stefan G. van Ravensteijn(Radboud University Nijmegen), Ingrid M.E. Desar(Radboud University Nijmegen), Mark A.J. Gorris(Salk Institute for Biological Studies), Maikel JL. Nederkoorn(Radboud University Nijmegen), Yvonne M.H. Versleijen‐Jonkers(Radboud University Nijmegen), Melissa H.S. Hillebrandt-Roeffen(Radboud University Nijmegen), Richarda M. de Voer(Radboud University Nijmegen), Leonie I. Kroeze(Radboud University Nijmegen), Marije E. Weidema(Radboud University Nijmegen), Uta Flucke(Princess Máxima Center), Kiek Verrijp, Tessa J.J. de Bitter(Radboud University Nijmegen)
Cited by 2
Related Papers
Predicting the functional states of human iPSC-derived neurons with single-cell RNA-seq and electrophysiology
|Molecular Psychiatry|2016|168
ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition
|Blood|2021|157
Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.
|PubMed|1994|149
Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations
|Acta Neuropathologica|2018|143
Solve-RD: systematic pan-European data sharing and collaborative analysis to solve rare diseases
|European Journal of Human Genetics|2021|104